5 January 2023 in Rhizosphere
15 January 2019 in The Journal of Immunology
The intracellular pathway of cross-presentation, which allows MHC class I–restricted presentation of peptides derived from exogenous Ags, remains poorly defined and may vary with the nature of the exogenous Ag and the type of APC. It can be cytosolic, characterized by proteasome and TAP dependency, or vacuolar, usually believed to be proteasome and TAP independent. Cross-presentation is particularly effective with long synthetic peptides, and we previously reported that the HLA-A2–restricted cross-presentation of a long peptide derived from melanoma Ag gp100 by human monocyte-derived immature dendritic cells occurred in a vacuolar pathway, making use of newly synthesized HLA-A2 molecules that follow a nonclassical secretion route. In this article, we show that the HLA-A1–restricted cross-presentation of a long peptide derived from tumor Ag MAGE-A3 by human monocyte-derived immature dendritic cells also follows a vacuolar pathway. However, as opposed to the HLA-A2–restricted peptide, cross-presentation of the HLA-A1–restricted peptide is TAP dependent. We show that this paradoxical TAP-dependency is indirect and reflects the need for TAP to load HLA-A1 molecules with peptides in the endoplasmic reticulum, to allow them to escape the endoplasmic reticulum and reach the vacuole, where peptide exchange with the cross-presented peptide likely occurs. Our results confirm and extend the involvement of the vacuolar pathway in the cross-presentation of long peptides, and indicate that TAP-dependency can no longer be used as a key criterion to distinguish the cytosolic from the vacuolar pathway of cross-presentation. They also stress the existence of an alternative secretory route for MHC class I, which will be worthy of further studies.
10 January 2022 in Urologic Oncology: Seminars and Original Investigations
1 January 2024 in JCO Oncology Practice
Methods for identifying high-volume hospitals affect conclusions about rural cancer care access.
2 May 2024 in Health Services Research
Objective: To examine differential changes in receipt of surgery at National Cancer Institute (NCI)‐designated comprehensive cancer centers (NCI‐CCC) and Commission on Cancer (CoC) accredited hospitals for patients with cancer more likely to be newly eligible for coverage under Affordable Care Act (ACA) insurance expansions, relative to those less likely to have been impacted by the ACA.Data Sources and Study Setting: Pennsylvania Cancer Registry (PCR) for 2010–2019 linked with discharge records from the Pennsylvania Health Care Cost Containment Council (PHC4).Study Design: Outcomes include whether cancer surgery was performed at an NCI‐CCC or a CoC‐accredited hospital. We conducted a difference‐in‐differences analysis, estimating linear probability models for each outcome that control for residence in a county with above median county‐level pre‐ACA uninsurance and the interaction between county‐level baseline uninsurance and cancer treatment post‐ACA to capture differential changes in access between those more and less likely to become newly eligible for insurance coverage (based on area‐level proxy). All models control for age, sex, race and ethnicity, cancer site and stage, census‐tract level urban/rural residence, Area Deprivation Index, and year‐ and county‐fixed effects.Data Collection/Extraction Methods: We identified adults aged 26–64 in PCR with prostate, lung, or colorectal cancer who received cancer‐directed surgery and had a corresponding surgery discharge record in PHC4.Principal Findings: We observe a differential increase in receiving care at an NCI‐CCC of 6.2 percentage points (95% CI: 2.6–9.8; baseline mean = 9.8%) among patients in high baseline uninsurance areas (p = 0.001). Our estimate of the differential change in care at the larger set of CoC hospitals is positive (3.9 percentage points [95% CI: −0.5‐8.2; baseline mean = 73.7%]) but not statistically significant (p = 0.079).Conclusions: Our findings suggest that insurance expansions under the ACA were associated with increased access to NCI‐CCCs.
20 May 2016 in Journal of Clinical Oncology
9539Background: Overall responses (OR) are reported in 34% of patients (pts) with advanced MEL treated with Pembro. Landmark survival is 66%/49% at 1-/2- years respectively. Pre-existing CD8+ T-cell infiltrates and IFN gene signature at tumor sites correlate with response to PD-1 blockade. To evaluate synergy between PD-1 blockade and Peg-IFN, we implemented a phase Ib study of Pembro/Peg-IFN combination with dose-seeking and dose-expansion phases in stage IV MEL. Methods: Pts with IV MEL were enrolled. Peg-IFN was dose-escalated using modified toxicity probability interval (mTPI) design in 3 cohorts (4 pts each) at 1,2 and 3 mcg/kg SC while Pembrolizumab was dosed at 2mg/kg q3weeks in all pts. Primary endpoints were safety and incidence of dose-limiting toxicities (DLTs). Secondary endpoints were OR rate (ORR), progression free and overall survival. Response was assessed every 12 weeks (RECIST 1.1). Sequential blood draws and tumor biopsies were collected. Here, we report on response observed in 24 pts t...